Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2018

View Archived Issues

LogicBio Therapeutics begins program for genome-editing therapy for methylmalonic acidemia

CFDA clears HG-146 to enter clinical trials for multiple myeloma

Intrommune Therapeutics launches financing campaign to support development of INT-301

Shionogi recaps progress of fourth quarter of fiscal 2017

SPRINT-MS trial: phase II results of ibudilast treatment in progressive multiple sclerosis

EVOLVE-MS-1 trial shows ALKS-8700 effects in patients with relapsing remitting multiple sclerosis

First patient dosed in the phase I/II trial of KB-103

Promising in vivo results for EP-055, a potential nonhormonal male contraceptive

Mainline Biosciences submits pre-IND meeting information package for MLB-1707

ROCK and PKC inhibitor AR-13503 in development for ocular disorders

Novel liver X receptor beta agonists divulged by Merck & Co.

Nimbus Lakshmi patents novel TYK2 inhibitors

Lundbeck identifies novel phosphodiesterase PDE1 inhibitors

Positive topline data from phase I trial of prophylactic CMV vaccine candidate VBI-1501

Novel P2X purinoceptor 7 antagonists discovered at Shionogi

Prelude Therapeutics discovers PRMT5 inhibitors

Patient recruitment ongoing in phase I trial of PF-06821497

Novel PTP-2C inhibitors discovered at DE Shaw Research, Relay Therapeutics

Pharmasum Therapeutics identifies novel DYRK inhibitors

MFN2 agonist restores mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A

Phosphodiesterase PDE4 inhibitors patented byTakeda

Lilly to acquire ARMO BioSciences

FDA identifies deficiencies during NDA review of Methylene Blue MMX

Phase I study of AVB-S6-500 demonstrates proof of mechanism

Researchers present nanoencapsulated hepatocyte enzymes to fight alcohol intoxication

SymBio enters joint research agreement with Keio University to evaluate Treakisym for SLE

CARB-X supports Talis' development of diagnostics to detect chlamydia and gonorrhea

KemPharm reports topline data from human abuse potential trial with KP-415 prodrug

FDA advisory committee votes in favor of Waylivra for familial chylomicronemia syndrome

Phase III GALATHEA trial of Fasenra in COPD does not meet primary endpoint

Lipimetix sublicenses Apo E mimetic peptide platform to Anji

New phase II proof-of-concept trial studies IXT-m200 in methamphetamine users